Baojun Chang

1.8k total citations
25 papers, 1.3k citations indexed

About

Baojun Chang is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Baojun Chang has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Cardiology and Cardiovascular Medicine and 5 papers in Oncology. Recurrent topics in Baojun Chang's work include Chemotherapy-induced organ toxicity mitigation (4 papers), Lanthanide and Transition Metal Complexes (3 papers) and Hippo pathway signaling and YAP/TAZ (3 papers). Baojun Chang is often cited by papers focused on Chemotherapy-induced organ toxicity mitigation (4 papers), Lanthanide and Transition Metal Complexes (3 papers) and Hippo pathway signaling and YAP/TAZ (3 papers). Baojun Chang collaborates with scholars based in United States, Japan and Netherlands. Baojun Chang's co-authors include Masayasu Inoue, Manabu Nishikawa, Xu Wu, Jeffery D. Molkentin, Petra Eder, Eisuke F. Sato, Richard D. Olson, Robert J. Boucek, Sidney Fleischer and Barry J. Cusack and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Baojun Chang

25 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Baojun Chang United States 16 611 399 242 173 156 25 1.3k
Rebecca S. Keller United States 19 704 1.2× 597 1.5× 161 0.7× 82 0.5× 102 0.7× 34 1.6k
Rong Tao China 25 916 1.5× 319 0.8× 435 1.8× 307 1.8× 107 0.7× 73 1.8k
Simone Polvani Italy 19 950 1.6× 263 0.7× 173 0.7× 80 0.5× 112 0.7× 38 1.4k
Huan He China 26 686 1.1× 288 0.7× 214 0.9× 150 0.9× 193 1.2× 65 1.5k
Shi Pan United States 19 1.0k 1.7× 187 0.5× 123 0.5× 55 0.3× 143 0.9× 28 1.6k
Virginia S. Hahn United States 13 527 0.9× 1.1k 2.8× 205 0.8× 87 0.5× 119 0.8× 29 1.6k
Melania Dovizio Italy 25 687 1.1× 318 0.8× 483 2.0× 49 0.3× 166 1.1× 63 2.0k
Wei Tian China 20 487 0.8× 57 0.1× 202 0.8× 90 0.5× 134 0.9× 48 1.0k
Zheng Gen Jin United States 24 825 1.4× 177 0.4× 111 0.5× 36 0.2× 93 0.6× 39 1.4k
Juan Du China 23 915 1.5× 94 0.2× 126 0.5× 88 0.5× 117 0.8× 73 1.5k

Countries citing papers authored by Baojun Chang

Since Specialization
Citations

This map shows the geographic impact of Baojun Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baojun Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baojun Chang more than expected).

Fields of papers citing papers by Baojun Chang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baojun Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baojun Chang. The network helps show where Baojun Chang may publish in the future.

Co-authorship network of co-authors of Baojun Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Baojun Chang. A scholar is included among the top collaborators of Baojun Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baojun Chang. Baojun Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shen, Yuanjun, Dmitry A. Goncharov, Andressa Peña, et al.. (2022). Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension. Science Signaling. 15(763). eabn2743–eabn2743. 14 indexed citations
2.
Jiang, Lifeng, Dmitry A. Goncharov, Yuanjun Shen, et al.. (2022). Akt-Dependent Glycolysis-Driven Lipogenesis Supports Proliferation and Survival of Human Pulmonary Arterial Smooth Muscle Cells in Pulmonary Hypertension. Frontiers in Medicine. 9. 886868–886868. 11 indexed citations
3.
Peña, Andressa, Ahasanul Kobir, Dmitry A. Goncharov, et al.. (2017). Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats. American Journal of Respiratory Cell and Molecular Biology. 57(5). 615–625. 36 indexed citations
4.
Kudryashova, Tatiana V., Dmitry A. Goncharov, Andressa Peña, et al.. (2016). HIPPO–Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine. 194(7). 866–877. 100 indexed citations
5.
Chang, Baojun, Kandice L. Tessneer, Xiaolei Liu, et al.. (2015). Epsin is required for Dishevelled stability and Wnt signalling activation in colon cancer development. Nature Communications. 6(1). 6380–6380. 28 indexed citations
6.
Liu, Xiaolei, Satish Pasula, Hoogeun Song, et al.. (2014). Temporal and spatial regulation of epsin abundance and VEGFR3 signaling are required for lymphatic valve formation and function. Science Signaling. 7(347). ra97–ra97. 51 indexed citations
7.
Tessneer, Kandice L., Xiaofeng Cai, Satish Pasula, et al.. (2013). Epsin Family of Endocytic Adaptor Proteins as Oncogenic Regulators of Cancer Progression. PubMed. 2(3). 144–150. 17 indexed citations
8.
Tessneer, Kandice L., Satish Pasula, Xiaofeng Cai, et al.. (2013). Endocytic Adaptor Protein Epsin Is Elevated in Prostate Cancer and Required for Cancer Progression. ISRN Oncology. 2013. 1–8. 15 indexed citations
9.
10.
11.
Chang, Baojun, et al.. (2009). Expression and Distribution of NADPH Oxidase Isoforms in Human Myometrium—Role in Angiotensin II-induced Hypertrophy1. Biology of Reproduction. 82(2). 305–312. 9 indexed citations
12.
Wu, Xu, Baojun Chang, N. Scott Blair, et al.. (2009). Plasma membrane Ca2+-ATPase isoform 4 antagonizes cardiac hypertrophy in association with calcineurin inhibition in rodents. Journal of Clinical Investigation. 119(4). 976–85. 66 indexed citations
13.
Iguchi, Taro, Manabu Nishikawa, Baojun Chang, et al.. (2004). Edaravone Inhibits Acute Renal Injury and Cyst Formation in Cisplatin-Treated Rat Kidney. Free Radical Research. 38(4). 333–341. 27 indexed citations
14.
Chang, Baojun, Manabu Nishikawa, Shuhei Nishiguchi, & Masayasu Inoue. (2004). L‐carnitine inhibits hepatocarcinogenesis via protection of mitochondria. International Journal of Cancer. 113(5). 719–729. 73 indexed citations
15.
Chang, Baojun, Manabu Nishikawa, Eisuke F. Sato, & Masayasu Inoue. (2003). Mice lacking inducible nitric oxide synthase show strong resistance to anti-Fas antibody-induced fulminant hepatitis. Archives of Biochemistry and Biophysics. 411(1). 63–72. 14 indexed citations
16.
Chang, Baojun, Manabu Nishikawa, Eisuke F. Sato, Kozo Utsumi, & Masayasu Inoue. (2002). l-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Archives of Biochemistry and Biophysics. 405(1). 55–64. 148 indexed citations
17.
Nishikawa, Manabu, et al.. (2001). Targeting Superoxide Dismutase to Renal Proximal Tubule Cells Inhibits Mitochondrial Injury and Renal Dysfunction Induced by Cisplatin. Archives of Biochemistry and Biophysics. 387(1). 78–84. 42 indexed citations
18.
19.
Chang, Baojun, D E Brenner, & Robert Gutman. (1989). Cellular pharmacology of doxorubicinol alone and combined with verapamil in pancreatic cancer cell lines.. PubMed. 9(2). 341–5. 5 indexed citations
20.
Olson, Richard D., Phillip S. Mushlin, Dean E. Brenner, et al.. (1988). Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.. Proceedings of the National Academy of Sciences. 85(10). 3585–3589. 299 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca S. Keller Breakdown of academic impact, for papers by Rong Tao Breakdown of academic impact, for papers by Simone Polvani Breakdown of academic impact, for papers by Huan He Breakdown of academic impact, for papers by Shi Pan Breakdown of academic impact, for papers by Virginia S. Hahn Breakdown of academic impact, for papers by Melania Dovizio Breakdown of academic impact, for papers by Wei Tian Breakdown of academic impact, for papers by Zheng Gen Jin Breakdown of academic impact, for papers by Juan Du
Rankless by CCL
2026